These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 34923848)

  • 21. Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction.
    Drachman B; Damy T; Hanna M; Wang R; Angeli FS; Garcia-Pavia P
    Eur J Heart Fail; 2024 Sep; 26(9):2038-2046. PubMed ID: 38932583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.
    Kuyama N; Takashio S; Oguni T; Yamamoto M; Hirakawa K; Ishii M; Hanatani S; Oda S; Matsuzawa Y; Usuku H; Yamamoto E; Hirai T; Ueda M; Tsujita K
    J Am Heart Assoc; 2024 May; 13(10):e034518. PubMed ID: 38761073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
    Sperry BW; Hanna M; Maurer MS; Nativi-Nicolau J; Floden L; Stewart M; Wyrwich KW; Barsdorf AI; Kapadia H; Spertus JA
    JAMA Cardiol; 2023 Mar; 8(3):275-280. PubMed ID: 36723935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.
    Li B; Alvir J; Stewart M
    Cardiol Ther; 2020 Dec; 9(2):535-540. PubMed ID: 32524297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    Am J Cardiol; 2021 Feb; 141():98-105. PubMed ID: 33220323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure.
    Ghoneem A; Bhatti AW; Khadke S; Mitchell J; Liu J; Zhang K; Trachtenberg B; Wechalekar A; Cheng RK; Baron SJ; Nohria A; Lenihan D; Ganatra S; Dani SS
    Curr Probl Cardiol; 2023 Jun; 48(6):101667. PubMed ID: 36828040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G
    Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
    Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.
    Bhambri R; Colavecchia AC; Bruno M; Chen Y; Alvir J; Roy A; Kemner J; Crowley A; Benjumea D; Gilstrap L
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):197-206. PubMed ID: 36780092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Octogenarian Patients Treated with Tafamidis for Transthyretin Amyloid Cardiomyopathy.
    Sarkar A; Sanchez-Nadales A; Kunutsor SK; Hanna MA; Asher CR; Wolinsky DG
    Am J Cardiol; 2024 Mar; 214():144-148. PubMed ID: 38306809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
    Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
    Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
    Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy.
    Uemura K; Ichikawa Y; Nagai S; Nishihara Y; Todo S; Oota E; Odajima S; Takeuchi K; Kintsu M; Fukuda T; Hisamatsu E; Hirata KI; Tanaka H
    Heart Vessels; 2024 Sep; 39(9):810-817. PubMed ID: 38743105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tafamidis for the treatment of transthyretin amyloidosis.
    Lorenzini M; Elliott PM
    Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
    Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Garcia-Pavia P; Kristen AV; Drachman B; Carlsson M; Amass L; Angeli FS; Maurer MS;
    J Card Fail; 2024 Jun; ():. PubMed ID: 38909877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary.
    Grogan M; Davis MK; Crespo Leiro MG; Sultan MB; Gundapaneni B; Angeli FS; Hanna M
    Future Cardiol; 2024; 20(11-12):595-603. PubMed ID: 39258729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.